Aurinia Pharmaceuticals (FRA:IKAP) Institutional Ownership: 19.61% (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IKAP Aurinia Pharmaceuticals Inc FRA:IKAP
81 GF Score
Price €13.46
GF Value €12.35
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Institutional Ownership?

Aurinia Pharmaceuticals FRA:IKAP +2.24% 81 Institutional Ownership is 19.61% as of Jul. 27, 2026. GuruFocus rates FRA:IKAP with a GF Score™ of 81/100 and a GF Value™ of €12.35 (Fairly Valued). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aurinia Pharmaceuticals's institutional ownership is 19.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aurinia Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aurinia Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 90.25%.

Aurinia Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Institutional Ownership Chart

Aurinia Pharmaceuticals Historical Data

The historical data trend for Aurinia Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 17.15 17.38 17.55 17.52 17.71 17.86 18.01 18.15 18.96 19.61
FRA:IKAP
81GF Score
Aurinia Pharmaceuticals Inc FRA:IKAP
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 19.61% mean?
Aurinia Pharmaceuticals (FRA:IKAP) has a Institutional Ownership of 19.61% as of Jul. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Aurinia Pharmaceuticals and its competitors.
Is Aurinia Pharmaceuticals' Institutional Ownership too high?
Aurinia Pharmaceuticals' current Institutional Ownership is 19.61%. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Institutional Ownership compare to PVLA and URGN?
Aurinia Pharmaceuticals' Institutional Ownership of 19.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Institutional Ownership is 19.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (FRA:IKAP) is currently considered Fairly Valued. The stock's GF Value™ is €12.35, compared to a current price of €13.46 — trading 8.9% above its estimated fair value. The current Institutional Ownership is 19.61%. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Aurinia Pharmaceuticals (FRA:IKAP), the current Institutional Ownership is 19.61% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (FRA:IKAP) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of €13.46 is trading 8.9% above its estimated GF Value™ of €12.35. GuruFocus considers Aurinia Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:IKAP:

  • Institutional Ownership: 19.61%
  • GF Value™: €12.35 vs. price of €13.46 (8.9% above fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the FRA:IKAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Other Exchanges AUPH:USAIKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score

Get the complete analysis for FRA:IKAP

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.46
Price
€12.35
GF Value